The Global CEO Initiative (CEOi) on Alzheimer’s Disease, Sage Bionetworks, and IBM’s DREAM, recently announced the Alzheimer’s Disease Big Data (AD#1) Challenge at the Alzheimer’s Disease Summit: The Path to 2025.
Global CEO Initiative on Alzheimer’s Disease Announces a Big Data Challenge to Find New Predictors of Cognitive Decline
Boehringer Ingelheim to Sponsor the Bonnie J. Addario Lung Cancer Foundation’s Efforts to Promote Genetic Biomarker Testing
The Bonnie J. Addario Lung Cancer Foundation (ALCF) and Boehringer Ingelheim Pharmaceuticals, Inc. (BI) recently announced that BI will sponsor ALCF’s efforts to raise awareness about the importance of immediate genetic biomarker testing for patients with advanced non-small cell lung cancer (NSCLC).
The Michael J. Fox Foundation Leads Charge to Develop Alpha-Synuclein PET Tracer to Image Parkinson’s Disease Biomarker
The pursuit of an imaging tool to visualize the protein alpha-synuclein, the hallmark pathology of Parkinson’s disease (PD), in the brain is the subject of a paper published recently in the Journal of Parkinson’s Diseaseby three researchers from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The Foundation has assembled and leads a consortium to develop a radioactive PET tracer that could lead to better therapies and quality of life for Parkinson’s patients.
A major new study conducted in Ireland found that 20 percent of patients with established heart disease were not adequately protected by aspirin. Corgenix Medical Corporation, developers of the AspirinWorks® Test for aspirin effect, said the study adds more evidence to the importance of accurately measuring aspirin response by measuring levels of the biomarker thromboxane.
Research by ClinMet Scientific Founder and Colleagues Point to Enzyme that Restores Function in Diabetic Kidney Disease
ClinMet recently announced that researchers from The University of California, San Diego School of Medicine and colleagues have published new findings that could fundamentally change understanding of how diabetes-related diseases develop – and how they might be better treated.
Novogen Limited (Australian Securities Exchange: NRT and NASDAQ: NVGN), an Australian biotechnology company dedicated to developing drugs that provide long-term remission through the successful control of cancer stem cells, recently announced a joint venture with Yale University dedicated to developing personalized approaches to chemotherapy to fight ovarian cancer.
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced that it has entered into an agreement with Incyte Corporation to collaborate on the development of companion diagnostic tests for Incyte’s oncology drug programs, beginning with the Incyte IDO1 inhibitor program. As part of the agreement, Ventana will support Incyte’s personalized medicine healthcare strategies for cancer drug development using its vast expertise in companion diagnostics, immunohistochemistry technology platforms, and worldwide customer support network.
WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinic’s Center for Individualized Medicine
WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, recently announced a licensing agreement with Mayo Clinic’s Center for Individualized Medicine to expand WuXi’s collection of patient-derived xenograft (PDX) mouse models. These models will support the cancer drug discovery and personalized medicine efforts of WuXi’s global customers.
Landmark Study of More than 27,000 Women Shows Favorable Results of Roche’s CINtec PLUS Cytology Test
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, is pleased to announce the positive findings of the Primary ASC-US LSIL Marker Study (PALMS) that have been published in The Journal of the National Cancer Institute.
Researchers Able to Identify that Benign Tumors from Use of Oral Contraceptive Have a Greater Chance of Becoming Malignant
Although very rare, the use of oral contraceptive can lead to benign tumors in the liver. The tumors, known as hepatocellular adenomas, can become malignant. It is, however, difficult for physicians to assess the risk of these tumors becoming malignant.